The dynamics of drug consumption are in a continual state of flux. Businesses and governments are actively seeking to contain costs, and evidence suggests that they are succeeding. Recent data from the Centers for Medicare and Medicaid Services indicate that spending on prescription drugs increased 10.7% in 2003, compared with 14.9% in 2002, and other data suggest that the rate continues to ease lower.
Pharmacy benefit management companies (PBMs) like Medco
But there's also another, more direct method of containing costs: requiring higher co-payments.
A recent piece in The Wall Street Journal shows just how high co-payments could go. The report indicates that Georgia state employees now will have to pay as much as $100 if they want certain brand-name drugs. Among the drugs included in the priciest co-pay tier are Pfizer's
This is bad news for companies unlucky enough to have drugs not favored by benefit plans. It's hard to imagine consumers paying $30 to $100 if they have the option of paying just $10. Of course, makers of branded drugs aren't going to wither away, thanks to ongoing innovation. But investors also should expect the higher co-payment trend to boost major generic players like Teva Pharmaceutical
For related news, see:
Pfizer is a recommendation of the Motley Fool Inside Value newsletter service.
Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.